COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 8.28M | 7.55M | 7.05M | 8.61M | 9.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.28M | 7.55M | 7.05M | 8.61M | 9.00M |
| Cost of Revenue | 4.60M | 4.85M | 4.78M | 4.89M | 4.87M |
| Gross Profit | 3.68M | 2.70M | 2.28M | 3.72M | 4.13M |
| SG&A Expenses | 7.03M | 8.05M | 9.24M | 5.50M | 6.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.06M | 14.64M | 16.07M | 14.76M | 17.90M |
| Operating Income | -4.78M | -7.09M | -9.01M | -6.16M | -8.91M |
| Income Before Tax | -4.38M | -6.45M | -8.94M | -12.41M | -16.46M |
| Income Tax Expenses | 10.00K | 12.00K | 12.00K | 1.08M | 972.00K |
| Earnings from Continuing Operations | -4.39 | -6.46 | -8.95 | -13.50 | -17.43 |
| Earnings from Discontinued Operations | 10.94M | 10.51M | -1.41M | -1.41M | -1.41M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.55M | 4.05M | -10.36M | -14.91M | -18.84M |
| EBIT | -4.78M | -7.09M | -9.01M | -6.16M | -8.91M |
| EBITDA | -5.89M | -8.24M | -10.19M | -5.21M | -7.77M |
| EPS Basic | 6.31 | 3.93 | -9.83 | -14.20 | -18.04 |
| Normalized Basic EPS | -2.44 | -3.67 | -5.16 | -3.14 | -4.87 |
| EPS Diluted | 6.30 | 3.93 | -9.83 | -14.20 | -18.04 |
| Normalized Diluted EPS | -2.44 | -3.67 | -5.16 | -3.14 | -4.87 |
| Average Basic Shares Outstanding | 4.21M | 4.22M | 4.22M | 4.21M | 4.18M |
| Average Diluted Shares Outstanding | 4.21M | 4.22M | 4.22M | 4.21M | 4.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |